Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies
20 Marzo 2024 - 2:00PM
Business Wire
Celanese Corporation (NYSE: CE), a global specialty materials
and chemical company, and Secarna Pharmaceuticals GmbH & Co.
KG, a leading independent European antisense drug discovery and
development company, today announced a research collaboration for
the development of long-acting implants that deliver antisense
oligonucleotides (ASOs).
ASOs are synthetic molecules designed to target specific
messenger RNA to prevent the production of proteins implicated in
the progression of a wide range of diseases including
cardiometabolic, central nervous system, oncological and rare
diseases. Antisense therapy is an innovative,
commercially-validated therapeutic approach, but often requires
frequent administration or the delivery of large doses to achieve
uptake at the intended site of action, ultimately causing a high
treatment burden for patients.
The Celanese VitalDose® Drug Delivery Platform and Secarna’s
proprietary ASO Drug Discovery and Development Platform will be
used to develop ASO-eluting implants, which have the potential to
lessen the dosing frequency, minimize off-target immune responses
and improve targeting to provide better patient outcomes for a
range of indications. The VitalDose® Drug Delivery Platform
provides reliable, controlled-release performance and has a long
history of use in approved parenteral drug products in the United
States and Europe. It can be tuned to deliver months to years of
drug release and has demonstrated, stable ASO release over one
year.
“Collaborating with Secarna allows us to develop an innovative
implant that has the potential to significantly change the way
disease-modifying ASO therapies are administered,” said Cyonna
Holmes, global business strategy leader for Ophthalmology and RNA
at Celanese. “Our team is excited to use our unique Drug Delivery
Platform and expertise to help address the growing need for
patient-centric, targeted solutions for ASO therapies alongside
Secarna.”
Secarna’s proprietary ASO Drug Development and Discovery
Platform enables the company to discover novel therapies for
targets that are difficult to reach therapeutically with
conventional approaches. With several high value and innovative
programs, Secarna has validated its platform in various indications
such as cardiometabolic, immune-oncology, fibrotic/inflammatory
diseases and the central nervous system.
“We are looking forward to partnering with Celanese to combine
our industry-leading ASO platform with their VitalDose® drug
delivery technology,” said Konstantin Petropoulos, CBO of Secarna
Pharmaceuticals. “Together we see the potential to enhance the way
our targeted ASO therapies are delivered which ultimately serves
our shared goal: to make highly specific, potent, safe and
convenient therapeutic options available for patients who urgently
need them.”
Scientists at the Celanese Development & Feasibility Lab
will independently conduct portions of the planned research in a
dedicated pharmaceutical facility. For more information on Celanese
VitalDose® technology, visit www.vitaldose.com.
About Celanese
Celanese is a global leader in chemistry, producing specialty
material solutions used across most major industries and consumer
applications. Our businesses use our chemistry, technology and
commercial expertise to create value for our customers, employees
and shareholders. We are committed to sustainability by responsibly
managing the materials we create for their entire lifecycle and are
growing our portfolio of sustainable products to meet increasing
customer and societal demand. We strive to make a positive impact
in our communities and foster inclusivity across our teams.
Celanese is a Fortune 500 company that employs approximately 12,400
employees worldwide with 2023 net sales of $10.9 billion.
About Secarna Pharmaceuticals GmbH & Co. KG
Secarna Pharmaceuticals is the leading independent European
next-generation antisense drug discovery and development company
addressing high unmet medical needs in immuno-oncology and
immunology, as well as viral, neurodegenerative and cardiometabolic
diseases. Secarna’s mission is to maximize the performance and
output of its proprietary antisense oligonucleotide discovery and
development platform to generate highly specific, safe, and
efficacious best-in-class antisense therapies. With over 20
discovery and development programs, including both proprietary
pipeline projects and partnered programs, Secarna focuses on
targets in indications where antisense-based approaches have clear
potential benefits over other therapeutic modalities.
www.secarna.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240320982284/en/
Investor Relations Brandon Ayache +1 972 443 8509
brandon.ayache@celanese.com
Media Relations – Global Brian Bianco +1 972 443 4400
media@celanese.com
Secarna Contacts: Alexander Gebauer, MD PhD +49 89 215 46
375 Alexander.gebauer@secarna.com
For media inquiries Anne Hennecke/Vera Lang +49 211 529
252 15 secarna@mc-services.eu
Grafico Azioni Celanese (NYSE:CE)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Celanese (NYSE:CE)
Storico
Da Giu 2023 a Giu 2024